{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:23:58Z","timestamp":1794201838418,"version":"4.8.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA050947"],"award-info":[{"award-number":["R01-CA050947"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA178264"],"award-info":[{"award-number":["R01-CA178264"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01-155258"],"award-info":[{"award-number":["P01-155258"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Riney Family Myeloma Initiative"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200224"],"award-info":[{"award-number":["82200224"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021MH072"],"award-info":[{"award-number":["ZR2021MH072"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood. Here, we identify, via two in vitro genome-wide CRISPR screens probing Daratumumab resistance, KDM6A as an important regulator of sensitivity to Daratumumab-mediated antibody-dependent cellular cytotoxicity (ADCC). Loss of\n                    <jats:italic>KDM6A<\/jats:italic>\n                    leads to increased levels of H3K27me3 on the promoter of\n                    <jats:italic>CD38<\/jats:italic>\n                    , resulting in a marked downregulation in CD38 expression, which may cause resistance to Daratumumab-mediated ADCC. Re-introducing CD38 does not reverse Daratumumab-mediated ADCC fully, which suggests that additional KDM6A targets, including CD48 which is also downregulated upon\n                    <jats:italic>KDM6A<\/jats:italic>\n                    loss, contribute to Daratumumab-mediated ADCC. Inhibition of H3K27me3 with an EZH2 inhibitor resulted in CD38 and CD48 upregulation and restored sensitivity to Daratumumab. These findings suggest\n                    <jats:italic>KDM6A<\/jats:italic>\n                    loss as a mechanism of Daratumumab resistance and lay down the proof of principle for the therapeutic application of EZH2 inhibitors, one of which is already FDA-approved, in improving MM responsiveness to Daratumumab.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-45561-z","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T12:02:30Z","timestamp":1707912150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Epigenetic regulation of CD38\/CD48 by KDM6A mediates NK cell response in multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-7508","authenticated-orcid":false,"given":"Jiye","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9791-2553","authenticated-orcid":false,"given":"Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-2381","authenticated-orcid":false,"given":"Gongwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9463-6530","authenticated-orcid":false,"given":"Su","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ogiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-6795","authenticated-orcid":false,"given":"Tian-Yu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1060-9218","authenticated-orcid":false,"given":"Keiji","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johany","family":"Penailillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8850-0442","authenticated-orcid":false,"given":"Eugenio","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8375-6572","authenticated-orcid":false,"given":"Xiaoning","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Gulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tzu","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7344-9795","authenticated-orcid":false,"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teru","family":"Hideshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":false,"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"45561_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046\u20131060 (2011).","journal-title":"N. Engl. J. Med."},{"key":"45561_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrc746","volume":"2","author":"WM Kuehl","year":"2002","unstructured":"Kuehl, W. M. & Bergsagel, P. L. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer 2, 175\u2013187 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"45561_CR3","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-16-0868","volume":"22","author":"SK Kumar","year":"2016","unstructured":"Kumar, S. K. & Anderson, K. C. Immune therapies in multiple myeloma. Clin. Cancer Res. 22, 5453\u20135460 (2016).","journal-title":"Clin. Cancer Res."},{"key":"45561_CR4","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai, Y. T. et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112, 1329\u20131337 (2008).","journal-title":"Blood"},{"key":"45561_CR5","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","volume":"30","author":"S Lonial","year":"2012","unstructured":"Lonial, S. et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol. 30, 1953\u20131959 (2012).","journal-title":"J. Clin. Oncol."},{"key":"45561_CR6","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers, M. et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186, 1840\u20131848 (2011).","journal-title":"J. Immunol."},{"key":"45561_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","volume":"131","author":"MP Velasquez","year":"2018","unstructured":"Velasquez, M. P., Bonifant, C. L. & Gottschalk, S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131, 30\u201338 (2018).","journal-title":"Blood"},{"key":"45561_CR8","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1021\/jacs.5b01876","volume":"137","author":"NS Ramadoss","year":"2015","unstructured":"Ramadoss, N. S. et al. An anti-B cell maturation antigen bispecific antibody for multiple myeloma. J. Am. Chem. Soc. 137, 5288\u20135291 (2015).","journal-title":"J. Am. Chem. Soc."},{"key":"45561_CR9","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/leu.2017.219","volume":"31","author":"S Hipp","year":"2017","unstructured":"Hipp, S. et al. A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 31, 2278 (2017).","journal-title":"Leukemia"},{"key":"45561_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207\u2013221 (2020).","journal-title":"Lancet Oncol."},{"key":"45561_CR11","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","volume":"15","author":"H Ikeda","year":"2009","unstructured":"Ikeda, H. et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 15, 4028\u20134037 (2009).","journal-title":"Clin. Cancer Res."},{"key":"45561_CR12","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"45561_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni, L. & Kochenderfer, J. N. CAR T cell therapies for patients with multiple myeloma. Nat. Rev. Clin. Oncol. 18, 71\u201384 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"45561_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40265-015-0536-1","volume":"76","author":"K McKeage","year":"2016","unstructured":"McKeage, K. Daratumumab: First global approval. Drugs 76, 275\u2013281 (2016).","journal-title":"Drugs"},{"key":"45561_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40265-016-0540-0","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham, A. Elotuzumab: First global approval. Drugs 76, 397\u2013403 (2016).","journal-title":"Drugs"},{"key":"45561_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40265-020-01311-1","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Isatuximab: First Approval. Drugs 80, 905\u2013912 (2020).","journal-title":"Drugs"},{"key":"45561_CR17","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst, H. M. et al. Targeting CD38 with Daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373, 1207\u20131219 (2015).","journal-title":"N. Engl. J. Med."},{"key":"45561_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos, M. V. et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N. Engl. J. Med. 378, 518\u2013528 (2018).","journal-title":"N. Engl. J. Med."},{"key":"45561_CR19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A. et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N. Engl. J. Med. 375, 754\u2013766 (2016).","journal-title":"N. Engl. J. Med."},{"key":"45561_CR20","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"N van de Donk","year":"2018","unstructured":"van de Donk, N. & Usmani, S. Z. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front. Immunol. 9, 2134 (2018).","journal-title":"Front. Immunol."},{"key":"45561_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof, I. S. et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 128, 959\u2013970 (2016).","journal-title":"Blood"},{"key":"45561_CR22","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood.2019004332","volume":"136","author":"D Ogiya","year":"2020","unstructured":"Ogiya, D. et al. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood 136, 2334\u20132345 (2020).","journal-title":"Blood"},{"key":"45561_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/BF01697400","volume":"64","author":"R Leo","year":"1992","unstructured":"Leo, R. et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann. Hematol. 64, 132\u2013139 (1992).","journal-title":"Ann. Hematol."},{"key":"45561_CR24","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","volume":"132","author":"PL Fedele","year":"2018","unstructured":"Fedele, P. L. et al. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. Blood 132, 2166\u20132178 (2018).","journal-title":"Blood"},{"key":"45561_CR25","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/leu.2015.123","volume":"29","author":"IS Nijhof","year":"2015","unstructured":"Nijhof, I. S. et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia 29, 2039\u20132049 (2015).","journal-title":"Leukemia"},{"key":"45561_CR26","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1182\/blood-2017-03-770776","volume":"129","author":"E Garcia-Guerrero","year":"2017","unstructured":"Garcia-Guerrero, E. et al. Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood 129, 3386\u20133388 (2017).","journal-title":"Blood"},{"key":"45561_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","volume":"6","author":"W Wang","year":"2015","unstructured":"Wang, W., Erbe, A. K., Hank, J. A., Morris, Z. S. & Sondel, P. M. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front. Immunol. 6, 368 (2015).","journal-title":"Front. Immunol."},{"key":"45561_CR28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/ng.349","volume":"41","author":"G van Haaften","year":"2009","unstructured":"van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521\u2013523 (2009).","journal-title":"Nat. Genet."},{"key":"45561_CR29","doi-asserted-by":"publisher","first-page":"5783","DOI":"10.1158\/1078-0432.CCR-15-1790","volume":"22","author":"C Pawlyn","year":"2016","unstructured":"Pawlyn, C. et al. The spectrum and clinical impact of epigenetic modifier mutations in myeloma. Clin. Cancer Res. 22, 5783\u20135794 (2016).","journal-title":"Clin. Cancer Res."},{"key":"45561_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-01957-w","volume":"21","author":"T Zhang","year":"2020","unstructured":"Zhang, T., Zhang, Z., Dong, Q., Xiong, J. & Zhu, B. Histone H3K27 acetylation is dispensable for enhancer activity in mouse embryonic stem cells. Genome Biol 21, 45 (2020).","journal-title":"Genome Biol"},{"key":"45561_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1028-7","volume":"17","author":"B Li","year":"2016","unstructured":"Li, B. et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 17, 174 (2016).","journal-title":"Genome Biol."},{"key":"45561_CR32","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser, F. et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 21, 1433\u20131442 (2020).","journal-title":"Lancet Oncol"},{"key":"45561_CR33","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","volume":"23","author":"W Beguelin","year":"2013","unstructured":"Beguelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677\u2013692 (2013).","journal-title":"Cancer Cell"},{"key":"45561_CR34","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1158\/1078-0432.CCR-13-2499","volume":"20","author":"T Ezponda","year":"2014","unstructured":"Ezponda, T. & Licht, J. D. Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination. Clin. Cancer Res. 20, 5001\u20135008 (2014).","journal-title":"Clin. Cancer Res."},{"key":"45561_CR35","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1158\/0008-5472.CAN-13-1896","volume":"74","author":"JH Kim","year":"2014","unstructured":"Kim, J. H. et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res 74, 1705\u20131717 (2014).","journal-title":"Cancer Res"},{"key":"45561_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1101\/gad.1882610","volume":"24","author":"JK Wang","year":"2010","unstructured":"Wang, J. K. et al. The histone demethylase UTX enables RB-dependent cell fate control. Genes Dev 24, 327\u2013332 (2010).","journal-title":"Genes Dev"},{"key":"45561_CR37","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.celrep.2017.09.078","volume":"21","author":"T Ezponda","year":"2017","unstructured":"Ezponda, T. et al. UTX\/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition. Cell Rep 21, 628\u2013640 (2017).","journal-title":"Cell Rep"},{"key":"45561_CR38","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","volume":"1","author":"T Casneuf","year":"2017","unstructured":"Casneuf, T. et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 1, 2105\u20132114 (2017).","journal-title":"Blood Adv."},{"key":"45561_CR39","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1182\/blood.2020006200","volume":"136","author":"M Naeimi Kararoudi","year":"2020","unstructured":"Naeimi Kararoudi, M. et al. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood 136, 2416\u20132427 (2020).","journal-title":"Blood"},{"key":"45561_CR40","doi-asserted-by":"crossref","unstructured":"Pech M. F. et al. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. Elife 8, (2019).","DOI":"10.7554\/eLife.47362"},{"key":"45561_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29469-0","volume":"13","author":"D Bernareggi","year":"2022","unstructured":"Bernareggi, D. et al. CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity. Nat Commun. 13, 1899 (2022).","journal-title":"Nat Commun."},{"key":"45561_CR42","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41588-021-00889-w","volume":"53","author":"M Sheffer","year":"2021","unstructured":"Sheffer, M. et al. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nat Genet. 53, 1196\u20131206 (2021).","journal-title":"Nat Genet."},{"key":"45561_CR43","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood-2013-09-526590","volume":"123","author":"S Elias","year":"2014","unstructured":"Elias, S. et al. Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood 123, 1535\u20131543 (2014).","journal-title":"Blood"},{"key":"45561_CR44","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood.2022015646","volume":"140","author":"M Chiba","year":"2022","unstructured":"Chiba, M. et al. Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. Blood 140, 1951\u20131963 (2022).","journal-title":"Blood"},{"key":"45561_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng, Y. et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 4, 62 (2019).","journal-title":"Signal Transduct Target Ther."},{"key":"45561_CR46","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy, S. M. Tazemetostat: First Approval. Drugs 80, 513\u2013521 (2020).","journal-title":"Drugs"},{"key":"45561_CR47","doi-asserted-by":"crossref","unstructured":"Alzrigat, M., Jernberg-Wiklund, H. & Licht, J. D. Targeting EZH2 in multiple myeloma-multifaceted anti-tumor activity. Epigenomes 2, 16 (2018).","DOI":"10.3390\/epigenomes2030016"},{"key":"45561_CR48","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783\u2013784 (2014).","journal-title":"Nat. Methods"},{"key":"45561_CR49","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","volume":"12","author":"J Joung","year":"2017","unstructured":"Joung, J. et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat. Protoc. 12, 828\u2013863 (2017).","journal-title":"Nat. Protoc."},{"key":"45561_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol"},{"key":"45561_CR51","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico, A. et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44, e71 (2016).","journal-title":"Nucleic Acids Res."},{"key":"45561_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol"},{"key":"45561_CR53","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"45561_CR54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"45561_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol"},{"key":"45561_CR56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"45561_CR57","doi-asserted-by":"publisher","first-page":"W187","DOI":"10.1093\/nar\/gku365","volume":"42","author":"F Ramirez","year":"2014","unstructured":"Ramirez, F., Dundar, F., Diehl, S., Gruning, B. A. & Manke, T. deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res. 42, W187\u2013W191 (2014).","journal-title":"Nucleic Acids Res."},{"key":"45561_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-018-2139-9","volume":"19","author":"M Cornwell","year":"2018","unstructured":"Cornwell, M. et al. VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis. BMC Bioinformatics 19, 135 (2018).","journal-title":"BMC Bioinformatics"},{"key":"45561_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"45561_CR60","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"45561_CR61","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"45561_CR62","unstructured":"Picard2019toolkit. Picard toolkit. Broad Institute, GitHub repository. http:\/\/broadinstitute.github.io\/picard\/ (2019)."},{"key":"45561_CR63","unstructured":"Stark, R. & Brown, G. DiffBind: Differential binding analysis of ChIP-Seq peak data. https:\/\/bioconductor.org\/packages\/release\/bioc\/html\/DiffBind.html (2012)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45561-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45561-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45561-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T14:03:39Z","timestamp":1707919419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45561-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["45561"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-45561-z","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"17 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.C.A. serves on advisory boards to Pfizer, AstraZeneca, Janssen, Starton, Window, and Bristol Myers Squibb; and is a Founder of OncoPep, C4 Therapeutics, Dynamic Cell Therapies, and NextRNA. All the other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1367"}}